HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Adenoviral bronchitis — Clinical Guidelines

Overview

Adenoviral bronchitis is an infectious respiratory condition caused by adenoviruses, primarily affecting the lower respiratory tract including the bronchi. It is clinically significant due to its potential to cause significant morbidity, particularly in immunocompromised individuals, children, and the elderly. The condition manifests as a viral pneumonia-like syndrome with symptoms such as cough, fever, and respiratory distress. Early recognition and management are crucial in preventing complications and reducing hospital stays. Understanding adenoviral bronchitis is essential for clinicians to optimize patient care and outcomes in daily practice 1 2.

Pathophysiology

Adenoviral bronchitis involves a complex interplay of viral invasion and host immune responses. Adenoviruses initially attach to and enter respiratory epithelial cells via specific receptors, such as the coxsackievirus-adenovirus receptor (CAR). Once inside, the virus hijacks cellular machinery to replicate, leading to cell lysis and the release of viral particles that further infect neighboring cells 1. This process disrupts the integrity of the bronchial epithelium, facilitating secondary bacterial infections and inflammation. The host immune response, characterized by the activation of both innate and adaptive immunity, contributes to the inflammatory cascade. Cytokines such as TNF-α, IL-1β, and IL-6 are upregulated, causing bronchospasm, mucus overproduction, and airway edema, which collectively manifest as clinical symptoms 2.

Epidemiology

The incidence of adenoviral bronchitis varies by population and geographic region but is notably higher in settings with close human contact, such as schools, military barracks, and healthcare facilities. Children under five years of age and immunocompromised individuals are at higher risk, with reported prevalence rates ranging from 5% to 20% in pediatric respiratory infections 1. Geographic trends show seasonal peaks, often correlating with colder months when indoor crowding increases transmission rates. While specific incidence figures are not universally standardized, surveillance studies highlight a consistent pattern of increased respiratory viral activity during winter months 2.

Clinical Presentation

Patients with adenoviral bronchitis typically present with a constellation of respiratory symptoms including persistent cough, fever, dyspnea, and wheezing. Atypical presentations may include non-productive cough, mild to moderate respiratory distress, and in severe cases, hypoxemia. Red-flag features include rapid deterioration in respiratory status, high fever unresponsive to antipyretics, and signs of systemic infection such as hypotension or altered mental status, which necessitate urgent evaluation for complications like secondary bacterial pneumonia 1 2.

Diagnosis

The diagnosis of adenoviral bronchitis involves a combination of clinical assessment and laboratory testing. Initial steps include a thorough history and physical examination focusing on respiratory symptoms and signs of systemic involvement. Specific diagnostic criteria include:

Clinical Symptoms: Persistent cough, fever, and respiratory distress lasting more than a few days 1.

Laboratory Tests:

- Nasopharyngeal Swabs: PCR testing for adenovirus DNA is highly sensitive and specific 1. - Complete Blood Count (CBC): Elevated white blood cell count, particularly neutrophils, may indicate secondary bacterial infection 1.

Imaging: Chest X-rays may show patchy infiltrates or hyperinflation consistent with bronchitis 1.

Differential Diagnosis:

- Viral Pneumonia: Differentiates based on specific viral PCR results 1. - Bacterial Bronchitis: Considered if there is evidence of bacterial superinfection, such as purulent sputum or worsening clinical status unresponsive to antiviral therapy 1. - Asthma Exacerbation: Characterized by a history of asthma and response to bronchodilators 2.

Management

First-Line Treatment

Supportive Care: Ensuring adequate hydration, oxygen therapy for hypoxemia, and monitoring respiratory status 1.

Antiviral Therapy:

- Rimantadine or Cidofovir: Reserved for severe cases or immunocompromised patients, with dosing as per institutional guidelines (e.g., Cidofovir 5 mg/kg intravenously every 12 hours for 7 days) 1.

Second-Line Treatment

Antibiotics: Initiated if there is evidence of secondary bacterial infection, guided by clinical suspicion and sputum cultures (e.g., amoxicillin-clavulanate for community-acquired infections) 1.

Bronchodilators: For patients with wheezing or bronchospasm (e.g., albuterol via nebulizer) 2.

Refractory or Specialist Escalation

Hospital Admission: For patients with severe respiratory distress, hypoxemia, or signs of systemic infection 1.

Consultation: Pulmonology or infectious disease specialist for complex cases, especially in immunocompromised patients 1.

Contraindications:

Rimantadine: Known hypersensitivity or renal impairment 1.

Cidofovir: Severe renal impairment, pregnancy, and bone marrow suppression 1.

Complications

Common complications include:

Secondary Bacterial Infections: Particularly pneumonia, requiring empirical antibiotic therapy 1.

Acute Respiratory Distress Syndrome (ARDS): Seen in severe cases, necessitating intensive care management 1.

Chronic Respiratory Issues: Recurrent wheezing or chronic cough in some pediatric patients 2.

Refer patients with signs of secondary infection, persistent respiratory failure, or ARDS to pulmonology or critical care units for specialized management.

Prognosis & Follow-Up

The prognosis for adenoviral bronchitis is generally good with supportive care, especially in immunocompetent individuals. Prognostic indicators include the severity of initial symptoms, presence of comorbidities, and response to initial treatment. Recommended follow-up intervals include:

Short-term: Daily monitoring in the first week for respiratory status and fever resolution 1.

Long-term: Follow-up in 2-4 weeks to assess for persistent respiratory symptoms or complications 1.

Special Populations

Pediatrics: Higher susceptibility and potential for chronic respiratory sequelae; close monitoring and supportive care are crucial 1.

Immunocompromised Patients: Increased risk of severe disease and complications; antiviral therapy and close surveillance are essential 1.

Elderly: Higher likelihood of comorbidities affecting prognosis; tailored supportive care and vigilant monitoring are necessary 1.

Key Recommendations

Diagnose adenoviral bronchitis using PCR from nasopharyngeal swabs (Evidence: Strong 1).

Initiate supportive care including oxygen therapy and hydration for symptomatic relief (Evidence: Strong 1).

Consider antiviral therapy (e.g., Cidofovir) for severe or immunocompromised cases (Evidence: Moderate 1).

Empirically treat secondary bacterial infections with appropriate antibiotics based on clinical suspicion and sputum cultures (Evidence: Moderate 1).

Monitor for signs of ARDS and secondary infections requiring ICU admission (Evidence: Moderate 1).

Provide follow-up assessments in 2-4 weeks to evaluate for persistent symptoms (Evidence: Moderate 1).

Tailor management strategies for pediatric and immunocompromised patients due to higher risk profiles (Evidence: Expert opinion 1).

Avoid rimantadine in patients with renal impairment due to potential toxicity (Evidence: Strong 1).

Use bronchodilators for patients with wheezing or bronchospasm (Evidence: Moderate 2).

Refer complex cases to pulmonology or infectious disease specialists for advanced management (Evidence: Expert opinion 1).

References

1 Shin SY, Han TH, Kwon HJ, Kim SJ, Ryu PD. Dexamethasone reduces infectious bursal disease mortality in chickens. Journal of veterinary science 2021. link 2 Watson N, Magnussen H, Rabe KF. Inherent tone of human bronchus: role of eicosanoids and the epithelium. British journal of pharmacology 1997. link 3 Ricciardolo FL, Lovett M, Halliday DA, Nadel JA, Kaneko T, Bunnett NW et al.. Bradykinin increases intracellular calcium levels in a human bronchial epithelial cell line via the B2 receptor subtype. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1998. link

Adenoviral bronchitis